Insulin dose determination method and device based on growth hormone stimulation test

Abstract

The invention discloses an insulin dose determination method and device based on a growth hormone stimulation test. The method includes: obtaining clinical data of a patient, wherein the clinical dataat least comprises a minimum insulin dose calculation coefficient for inducing hypoglycemia of the patient; analyzing the correlation between the minimum insulin dose calculation coefficient and other data in the clinical data, wherein the other data in the clinical data at least includes a patient's fasting insulin level value, and patient's insulin level values at the 120-th minute and the 180-th minute in an oral glucose tolerance test; using a multiple linear regression analysis method to obtain an insulin dose calculation coefficient according to the correlation; and determining the insulin dose of the patient in a growth hormone stimulation test according to the insulin dose calculation coefficient. The method and device can accurately determine the insulin dose required by the patient in an ITT test, and then makes the ITT test more efficient and safer.

Description

technical field [0001] The invention relates to the field of clinical medicine, in particular to a method and device for determining insulin dosage based on a growth hormone stimulation test. Background technique [0002] Hypopituitarism is a relatively common clinical endocrine system disease, which can affect people of all ages. Gonadotropin is often the first deficiency in patients with this disease, followed by Growth Hormone (GH), and finally Thyroid Stimulating Hormone (TSH) and Adreno-cortico-tropic-hormone (ACTH). ). The onset of hypopituitarism is occult, the progress is relatively slow, and the condition is relatively complicated. At the same time, it is often missed or misdiagnosed. Therefore, the measurement of various pituitary hormone levels and the assessment of pituitary reserve capacity are very important for the diagnosis of the disease. [0003] Since the secretion of growth hormone is affected by blood sugar, amino acids, exercise and sleep, some physio...

AI Technical Summary

Problems solved by technology

[0004] The dosage of short-acting insulin in ITT is calculated as 0.1-0.15U per kilogram of body weight. However, in clinical applications and some reports at home and abroad, it has been found that during the implementation of ITT, this traditional dose of insulin often causes hypoglycemia to fail to be induced as scheduled. As a result of the failure of the test, many patients need to increase the dosage of insulin several times during the test to successfully induce hypoglycemia, especially for overweight and obese patients.

However, repeated addition of insulin during the implementation of ITT will not only prolong the test time and increase the workload of medical staff, but also may affect the patient's psychological state, and may even be life-threatening due to severe hypoglycemia induced by the accumulation of insulin in the body

Images